Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
Acq. announced
Pulmatrix, Inc. (PULM) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 8-K Quarterly results
Docs: "Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Update"
07/13/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
07/11/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Pulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine"
05/12/2023 8-K Quarterly results
Docs: "Pulmatrix Announces First Quarter 2023 Financial Results and Provides Corporate Update"
03/30/2023 8-K Quarterly results
02/06/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Pulmatrix Announces First Patient Dosed in Phase 2b Study of PUR1900 for Treatment of Allergic Bronchopulmonary Aspergillosis in Subjects with Asthma"
02/03/2023 8-K Quarterly results
01/25/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Pulmatrix to Host Key Opinion Leader Webinar “PUR3100 for the Treatment of Acute Migraine: Unlocking the Potential of DHE Treatment”"
01/11/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
01/04/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Pulmatrix Announces Positive Top Line Results from a Phase 1study with PUR3100, a Novel Orally Inhaled Dihydroergotamine , for Acute Migraine PUR3100 was safe and all doses had fewer GI side effects compared to IV DHE"
09/26/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Pulmatrix Announces Patient Dosing Completed for its Novel Inhaled Therapy PUR3100 for Acute Migraine"
08/10/2022 8-K Quarterly results
07/12/2022 8-K Quarterly results
06/15/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
04/29/2022 8-K Quarterly results
04/15/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Schedule of Fees"
03/29/2022 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits  I...
Docs: "Pulmatrix Announces Year-End and Q4 Financial 2021 Results and Provides Corporate Update"
03/21/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Pulmatrix Announces Positive Top-Line Data Evaluating PUR1800 in Patients with Stable COPD"
03/17/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Pulmatrix Regains Compliance With Nasdaq Listing Requirements"
03/04/2022 8-K Quarterly results
02/24/2022 8-K Quarterly results
02/15/2022 8-K Other Events  Interactive Data
02/11/2022 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
12/17/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Letter re: Pulmatrix, Inc. Registration Statement on Form S-3, Registration No. 333-256502",
"Investor Contact:"
12/15/2021 8-K Quarterly results
12/07/2021 8-K Quarterly results
11/10/2021 8-K Quarterly results
Docs: "Pulmatrix Reports Third Quarter 2021 Financial Results and Provides Business Update Pulmazole contract dispute with Cipla resolved, expect to initiate Ph2b study in Q1 2023 for treatment of Allergic Bronchopulmonary Aspergillosis PUR3100 IND submission planned for Q1 2022 with Ph1study start anticipated in Q2 2022 PUR1800 Ph1b study on track for top-line data in Q1 2022"
11/09/2021 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "SECOND AMENDMENT TO THE DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
"Pulmatrix Announces Resolution of Contract Dispute with Cipla"
08/23/2021 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
08/10/2021 8-K Quarterly results
Docs: "Pulmatrix Reports Second Quarter 2021 Financial Results and Provides Business Update"
07/27/2021 8-K Resignation/termination of a director, Appointed a new director
Docs: "Investor Contact"
06/17/2021 8-K Quarterly results
06/16/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy